Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01092702 · ClinicalTrials.gov registry record · Phase 2
Varenicline For Smokers In Recovery From Alcohol Dependence
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT01092702: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT01092702 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01092702, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
The goal of this proposal is to explore the potential effectiveness of varenicline to treat tobacco dependence among recovering alcoholic smokers who, as a group, are at high risk for tobacco-caused morbidity and mortality. In this open-label phase II clinical trial, we are proposing to enroll 32 recovering alcoholic smokers who are motivated to stop smoking. After the initial up titration of varenicline in week 1, all 32 subjects will receive a total of 2 mg/day of varenicline for 12 weeks. In addition to receiving varenicline, all subjects will receive brief behavioral counseling and our standard intervention at each visit during participation in the study.
Interventions
- DRUG Varenicline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01092702
The ClinicalTrials.gov registry entry for NCT01092702 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Varenicline is the first listed.
NCT01092702 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01092702 about?
NCT01092702 is a clinical study titled "Varenicline For Smokers In Recovery From Alcohol Dependence". The goal of this proposal is to explore the potential effectiveness of varenicline to treat tobacco dependence among recovering alcoholic smokers who, as a group, are at high risk for tobacco-caused morbidity and mortality. In this open-label phase II clinical trial, we are proposing to enroll 32 re...
What is the current status of trial NCT01092702?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2008-04. Estimated completion is 2009-09.
What interventions are being tested in trial NCT01092702?
The interventions under investigation include: Varenicline (DRUG).
Who is sponsoring clinical trial NCT01092702?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.